BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The 10 Most Persuasive Forerunners in Innovation - 2Brazil's agricultural research agency gets cannabis research greenlight
- 34 Excellent Remote Headphones of 2024
- 4From Lounge chair to Money: Online Positions That Will Change Your Profession
- 5Understanding Various Sorts of Financial balances: An Extensive Outline
- A Manual for Nations to Make a trip To
- Individual Preparation Administrations to Raise Your Wellness Process
- An Excursion Through Renowned Western Network programs
- Share your pick for the riding area that characterizes your surf undertakings!
- When fake data is a good thing – how synthetic data trains AI to solve real problems
- Step by step instructions to Guarantee Your Lab Precious stone is Morally Obtained
- Becoming amazing at Systems administration: Individual and Expert Tips
- 5 Indoor Plants That Further develop Air Quality
- AstraZeneca to invest $2 billion as part of US manufacturing push
